Will mounjaro help pcos

Will mounjaro help pcos

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

£145.00UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 26 May 2026

Last Updated: 13 August 2026

Polycystic ovary syndrome, or PCOS, is one of the most common hormonal conditions affecting women of reproductive age in the UK, and yet it remains one of the most under-discussed and poorly managed. If you have been struggling with weight gain, irregular periods, stubborn insulin resistance, or the emotional toll that PCOS brings, you are far from alone. Many women are now asking whether newer weight loss medications like Mounjaro could finally offer some real relief, and it is a genuinely important question worth exploring in detail.

Quick Summary

Mounjaro (tirzepatide) works on two key gut hormones that regulate insulin and appetite, making it particularly relevant for women with PCOS who deal with insulin resistance and weight challenges. Early clinical evidence and real-world experience suggest it may offer meaningful benefits beyond simple weight loss, though it is not yet licensed specifically for PCOS in the UK.

  • PCOS is closely linked to insulin resistance, which Mounjaro directly targets
  • Weight loss from Mounjaro can significantly improve hormonal imbalances in PCOS
  • Mounjaro is not currently licensed for PCOS but may be prescribed off-label
  • Benefits may include improved menstrual regularity, reduced androgens, and better fertility outcomes
  • A clinician assessment is essential before starting Mounjaro for PCOS management

PCOS & Mounjaro Benefit Estimator

Answer a few quick questions to see how Mounjaro might help your PCOS symptoms.

Table of Contents

  1. What Is PCOS and Why Is It So Hard to Manage?
  2. How Mounjaro Works and Why It Is Relevant to PCOS
  3. Will Mounjaro Help PCOS? The Evidence So Far
  4. Which PCOS Symptoms Could Mounjaro Improve?
  5. Who Is Eligible for Mounjaro with PCOS in the UK?
  6. Mounjaro vs Other PCOS Treatments: A Comparison
  7. Key Takeaways
  8. When to Seek Professional Advice
  9. Scientific References
  10. FAQs

What Is PCOS and Why Is It So Hard to Manage?

Polycystic ovary syndrome affects approximately one in ten women of reproductive age in the UK, making it one of the most prevalent endocrine disorders in the country. Despite this, many women report waiting years for a diagnosis and feeling dismissed by healthcare providers. The condition is characterised by a hormonal imbalance involving elevated androgens (male hormones), disrupted ovulation, and the development of small follicles on the ovaries. But its impact goes far beyond reproductive health.

One of the most significant and least-discussed aspects of PCOS is insulin resistance, which is present in up to 70% of women with the condition, regardless of body weight. When cells become resistant to insulin, the pancreas compensates by producing more, and high circulating insulin levels then stimulate the ovaries to produce excess androgens. This creates a vicious cycle that worsens weight gain, disrupts periods, causes acne and excess hair growth, and makes conception difficult. For many women, no amount of healthy eating or exercise seems to break this cycle, which is why so many are now asking whether will Mounjaro help PCOS is a question with a genuinely promising answer.

The frustration is real and valid. Standard treatment options such as the combined oral contraceptive pill, metformin, and lifestyle advice all have their limitations. The pill masks symptoms rather than addressing the root cause, metformin works modestly for insulin resistance but rarely delivers meaningful weight loss, and lifestyle advice alone is often insufficient when the underlying hormonal and metabolic dysfunction is working against you at every turn.

  • PCOS affects 1 in 10 UK women of reproductive age
  • Insulin resistance is present in up to 70% of PCOS cases
  • Symptoms include irregular periods, weight gain, acne, and excess hair growth
  • Standard treatments often fail to address the metabolic root cause
  • Women with PCOS face higher long-term risks of type 2 diabetes and cardiovascular disease

How Mounjaro Works and Why It Is Relevant to PCOS

Mounjaro (tirzepatide) is a once-weekly injectable medication that works by activating two gut hormones simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-action mechanism is what sets it apart from older GLP-1 medications like semaglutide. By targeting both receptors, Mounjaro delivers superior insulin sensitisation, appetite regulation, and metabolic improvements compared to single-receptor agonists.

For women with PCOS, this dual mechanism is particularly meaningful. GLP-1 receptor activation reduces appetite and slows gastric emptying, helping to reduce caloric intake naturally. It also stimulates insulin secretion in a glucose-dependent manner, meaning it only triggers insulin release when blood sugar is actually elevated, which significantly reduces the risk of hypoglycaemia. The GIP component adds a further layer of metabolic benefit by improving fat metabolism and increasing the sensitivity of fat cells to insulin. Together, these actions begin to unpick the very insulin resistance that drives PCOS hormonal dysfunction. You can learn more about how tirzepatide compares to other GLP-1 treatments in our guide to GLP-1 agonist effectiveness comparisons.

Will Mounjaro help PCOS through weight loss alone? The answer is no — and this is an important distinction. The benefits of Mounjaro in the context of PCOS appear to go beyond simple caloric restriction. Clinical data from tirzepatide trials has shown improvements in insulin sensitivity, reductions in fasting insulin levels, and decreases in inflammatory markers, all of which are directly relevant to PCOS pathology even in women who do not lose a dramatic amount of weight.

  • Mounjaro activates both GLP-1 and GIP receptors, unlike semaglutide which targets only GLP-1
  • Dual-action mechanism improves insulin sensitivity directly, not just through weight loss
  • Reduces fasting insulin levels, which can lower androgen production in the ovaries
  • Decreases systemic inflammation, which is elevated in most women with PCOS
  • Suppresses appetite naturally, helping women overcome the metabolic disadvantage of PCOS

Will Mounjaro Help PCOS? The Evidence So Far

The question of will Mounjaro help PCOS is one that researchers are actively investigating. While there are no large-scale randomised controlled trials specifically examining tirzepatide in women with PCOS at the time of writing, the evidence available is encouraging and scientifically logical. The SURMOUNT trials, which evaluated tirzepatide for weight loss, included many participants with metabolic syndrome and insulin resistance, conditions that share significant overlap with PCOS. These trials consistently showed that Mounjaro reduced HbA1c, fasting insulin, body weight, and waist circumference, all markers of central importance in PCOS management.

Additionally, smaller studies and case series examining GLP-1 receptor agonists as a class in women with PCOS have shown improvements in menstrual regularity, reductions in free androgen index, and in some cases restoration of ovulation. Because Mounjaro has a more potent effect on insulin resistance than older GLP-1 medications, there is good reason to expect these benefits to be at least as significant, if not more so, with tirzepatide. Our detailed guide on GLP-1 and fertility covers this evidence in depth.

It is also worth noting that the mechanism is well-understood from a physiological standpoint. When insulin levels fall due to improved insulin sensitivity, the ovaries receive fewer signals to ovulate abnormally and produce excess testosterone. This can lead to a gradual normalisation of the LH-to-FSH ratio, more regular ovulation, and a reduction in androgen-driven symptoms such as hirsutism and acne. Weight loss of even 5 to 10% of body weight has been shown in clinical studies to restore menstrual regularity in over 50% of overweight women with PCOS, and Mounjaro typically delivers far greater weight loss than this. Check out the Mounjaro week-by-week weight loss guide for realistic expectations.

  • SURMOUNT trial data shows significant reductions in insulin resistance relevant to PCOS
  • GLP-1 class drugs have demonstrated menstrual cycle improvements in PCOS studies
  • Mounjaro's dual mechanism suggests stronger benefits than semaglutide alone
  • 5–10% weight loss can restore ovulation in over 50% of overweight PCOS women
  • Reductions in free androgen index reported with GLP-1 use in PCOS

Which PCOS Symptoms Could Mounjaro Improve?

PCOS presents differently in every woman, but certain symptoms are so commonly reported that they define the lived experience of the condition. Understanding exactly which symptoms Mounjaro is most likely to help with can give women a more realistic picture of what to expect. This is not a cure for PCOS, but it may be a genuinely transformative tool for managing several of its most debilitating aspects.

Irregular or absent periods are among the most distressing symptoms for women with PCOS, particularly those hoping to conceive. By reducing insulin levels and facilitating weight loss, Mounjaro can help restore more regular ovulatory cycles. Weight-related androgen excess is a key driver of anovulation in PCOS, and as tirzepatide reduces both weight and insulin resistance simultaneously, the hormonal environment becomes more conducive to regular menstruation. It is important to note, however, that Mounjaro is not safe to use during pregnancy and must be stopped well before conception is attempted — our Mounjaro and pregnancy guidance explains this in full.

Excess weight and abdominal fat accumulation, which worsen insulin resistance and drive PCOS, are directly addressed by Mounjaro's appetite-suppressing and metabolic effects. Clinical trials have shown average weight reductions of 15 to 22% of body weight over 72 weeks, which is significantly greater than any other approved non-surgical weight loss treatment currently available in the UK. For women with PCOS whose weight has been resistant to conventional dieting, this level of effectiveness can feel genuinely life-changing. You can also explore our complete guide to Mounjaro weight loss injections for more detail.

  • Menstrual irregularity — may improve as insulin levels fall and androgens reduce
  • Weight gain and abdominal obesity — directly targeted with average 15–22% body weight loss
  • Acne and oily skin — often driven by excess androgens, which can reduce with improved insulin sensitivity
  • Excess hair growth (hirsutism) — may gradually improve as testosterone levels normalise
  • Fatigue and brain fog — linked to insulin dysregulation, which Mounjaro helps correct
  • Elevated blood sugar and pre-diabetes risk — directly reduced by tirzepatide's dual mechanism

Who Is Eligible for Mounjaro with PCOS in the UK?

One of the most common questions from women with PCOS is whether they can actually access Mounjaro for this condition in the UK. The current position is that Mounjaro holds MHRA approval for the treatment of type 2 diabetes and, more recently, for chronic weight management in adults with a BMI of 30 or above (or 27.5 and above with weight-related comorbidities). It is not specifically licensed for PCOS as a standalone indication.

However, this does not mean it is inaccessible. Clinicians in the UK can prescribe Mounjaro off-label for women with PCOS who meet the weight criteria, particularly when the PCOS is accompanied by insulin resistance, pre-diabetes, or obesity. In practice, many women with PCOS who have a BMI of 30 or above, or 27.5 or above with conditions such as hypertension or impaired glucose tolerance, will meet the standard criteria for Mounjaro even without PCOS being the stated primary indication. For clarity on what is needed to access this medication, our guide to Mounjaro eligibility requirements in the UK is an excellent starting point. You can also review the UK regulatory status of Mounjaro for PCOS for the most up-to-date information.

Through Cured Pharmacy, women can complete an online medical assessment and be reviewed by a UK-based prescriber who will evaluate whether Mounjaro is appropriate for their specific situation. This means that even if your GP has not discussed this option with you, you may still be able to access it through a legitimate private prescription pathway. The assessment considers your BMI, medical history, current medications, and symptoms to ensure safe and appropriate prescribing.

  • Mounjaro is not licensed for PCOS specifically but can be prescribed off-label
  • Eligible if BMI is 30 or above, or 27.5 or above with weight-related health conditions
  • PCOS with insulin resistance or pre-diabetes strengthens the clinical case for prescribing
  • A medical assessment is required from a UK-registered prescriber
  • Not suitable during pregnancy — effective contraception is essential while on treatment

Mounjaro vs Other PCOS Treatments: A Comparison

To put Mounjaro in perspective, it helps to compare it directly against the treatments most commonly used for PCOS in the UK. Every woman's situation is different, and combination therapy may sometimes be the most effective approach, but this table provides a clear overview of how Mounjaro stacks up against the alternatives.

Treatment Targets Insulin Resistance Weight Loss Effect Improves Periods Reduces Androgens Available on NHS
Mounjaro (Tirzepatide) Yes — dual GLP-1/GIP action 15–22% average body weight loss Yes (indirectly) Yes (indirectly) Limited (private prescription available)
Metformin Yes — modest improvement Minimal (1–3 kg) Moderate improvement Slight reduction Yes
Combined Oral Contraceptive Pill No None (may cause slight gain) Yes (artificially regulated) Yes (suppresses androgens) Yes
Wegovy (Semaglutide) Yes — GLP-1 only 10–15% average body weight loss Yes (indirectly) Yes (indirectly) Limited (NHS specialist only)
Lifestyle Changes Only Partially Variable (5–10% realistic) Possible with 5%+ loss Possible with weight loss Yes (GP referral)
Spironolactone / Anti-androgens No None Minimal Yes (direct anti-androgen) Limited (specialist only)

Key Takeaways

  • Mounjaro's dual GLP-1/GIP mechanism directly targets the insulin resistance that underlies most cases of PCOS, making it mechanistically well-suited to the condition
  • Clinical evidence from tirzepatide trials and GLP-1 class studies in PCOS strongly suggests potential benefits for menstrual regularity, androgen levels, and metabolic health
  • Average weight loss of 15 to 22% with Mounjaro far exceeds what can be achieved with metformin or lifestyle changes alone, and even modest weight loss has a profound impact on PCOS symptoms
  • Mounjaro is not currently licensed for PCOS in the UK but can be accessed via off-label private prescription for eligible women who meet BMI criteria
  • Mounjaro must be stopped before pregnancy is attempted, and effective contraception must be used throughout treatment

When to Seek Professional Advice

If you have PCOS and are considering Mounjaro, it is essential to have a proper clinical assessment rather than attempting to self-prescribe or purchase from unregulated sources. There are several specific situations in which you should seek professional advice urgently or before proceeding with any new treatment.

You should speak to a healthcare professional if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, as Mounjaro is contraindicated in these cases. Women with a history of pancreatitis, severe gastrointestinal disease, or certain kidney conditions should also seek specialist guidance. If you are currently taking other medications for PCOS, including metformin, anti-androgens, or the contraceptive pill, a prescriber needs to review potential interactions and whether any adjustments are needed.

If you are trying to conceive, pregnant, or breastfeeding, Mounjaro is not appropriate and should not be used. Women who experience any unusual symptoms after starting Mounjaro, including severe abdominal pain, vision changes, or allergic reactions, should stop taking it and seek urgent medical attention. For general questions about Mounjaro's side effects and safety, our guide to understanding side effects when starting GLP-1 treatment provides helpful reassurance.

Scientific References

  1. National Institute for Health and Care Excellence (NICE). Polycystic Ovary Syndrome: Identification and Management. NICE Guideline NG88. NICE, 2023. [Accessed 13 August 2026]
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 2022. (SURMOUNT-1 Trial Data). [Accessed 13 August 2026]
  3. Balen AH, et al. The management of anovulatory infertility in women with polycystic ovary syndrome. BMJ, 2021. [Accessed 13 August 2026]
  4. NICE Clinical Guideline CG156: Fertility problems: assessment and treatment, NICE, 2013 (updated 2017) [Accessed 13 August 2026]
  5. Mounjaro 5mg solution for injection in pre-filled pen – Summary of Product Characteristics, Electronic Medicines Compendium (EMC), Eli Lilly, 2023 [Accessed 13 August 2026]
  6. MHRA approves Mounjaro (tirzepatide) for type 2 diabetes in the UK, Medicines and Healthcare products Regulatory Agency (MHRA), 2023 [Accessed 13 August 2026]
  7. Teede HJ et al., Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome, Human Reproduction, 2023 [Accessed 13 August 2026]
  8. Jensterle M et al., Efficacy of GLP-1 receptor agonists in polycystic ovary syndrome: a meta-analysis, Frontiers in Endocrinology, 2022 [Accessed 13 August 2026]
  9. Insulin resistance and its clinical relevance, Diabetes UK position statement, Diabetes UK, 2023 [Accessed 13 August 2026]
  10. Fertility problems: assessment and treatment, NICE Guideline CG156, NICE, 2013 (updated 2017) [Accessed 13 August 2026]
  11. Mounjaro (tirzepatide) Summary of Product Characteristics, European Medicines Agency / EMC, 2023 [Accessed 13 August 2026]
  12. Tirzepatide and its potential role in obesity and metabolic syndrome, Diabetes on the Net, 2023 [Accessed 13 August 2026]
  13. Jiang Y et al., GLP-1 receptor agonists and polycystic ovary syndrome: a systematic review, Reproductive Health, 2022 [Accessed 13 August 2026]
  14. Type 2 diabetes in adults: management, NICE Guideline NG28, NICE, 2022 [Accessed 13 August 2026]
  15. Long-term Consequences of Polycystic Ovary Syndrome, Green-top Guideline No. 33, Royal College of Obstetricians and Gynaecologists, 2014 [Accessed 13 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • • Reviewed by UK-based prescribers
  • • Takes under 3 minutes
  • • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My Assessment Returning Customer? Log In to Your Account

Frequently Asked Questions

Will Mounjaro help PCOS symptoms like irregular periods?

Yes, by reducing insulin resistance and promoting weight loss, Mounjaro may help regulate menstrual cycles in women with PCOS, though individual results vary.

Is Mounjaro licensed specifically for PCOS in the UK?

No, Mounjaro is not currently licensed for PCOS in the UK, but it can be prescribed off-label by a clinician for eligible women with PCOS and obesity or type 2 diabetes.

How long does it take for Mounjaro to improve PCOS symptoms?

Most women begin to notice improvements in insulin sensitivity and weight within 4 to 12 weeks, with hormonal benefits often becoming more apparent over 3 to 6 months.

Can Mounjaro improve fertility in women with PCOS?

Indirectly yes, as weight loss and improved insulin sensitivity from Mounjaro can restore ovulation in some women with PCOS, but it should not be used during pregnancy.

Back to blog